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Background: To be effective, orally administered live Salmonella vaccines must first survive their encounter with
the low pH environment of the stomach. To enhance survival, an antacid is often given to neutralize the acidic
environment of the stomach just prior to or concomitant with administration of the vaccine. One drawback of this
approach, from the perspective of the clinical trial volunteer, is that the taste of a bicarbonate-based acid
neutralization system can be unpleasant. Thus, we explored an alternative method that would be at least as
effective as bicarbonate and with a potentially more acceptable taste. Because ingestion of protein can rapidly
buffer stomach pH, we examined the possibility that the protein-rich Ensure® Nutrition shakes would be effective
alternatives to bicarbonate.
Results: We tested one Salmonella enterica serovar Typhimurium and three Salmonella Typhi vaccine strains and
found that all strains survived equally well when incubated in either Ensure® or bicarbonate. In a low gastric pH
mouse model, Ensure® worked as well or better than bicarbonate to enhance survival through the intestinal tract,
although neither agent enhanced the survival of the S. Typhi test strain possessing a rpoS mutation.
Conclusions: Our data show that a protein-rich drink such as Ensure® Nutrition shakes can serve as an alternative
to bicarbonate for reducing gastric pH prior to administration of a live Salmonella vaccine.
Keywords: Salmonella vaccine, Gastric pH neutralization, Bicarbonate, Ensure nutrition shake, Low gastric pH
mouse modelBackground
Live recombinant attenuated Salmonella-vectored vac-
cines (RASV) have the potential to provide protection
against a variety of human non-Salmonella pathogens at
low cost. By using the Salmonella cells to express a
heterologous protective antigen, RASVs can induce
humoral and cellular immune responses directed at a
pathogen of interest [1]. RASVs have the additional ad-
vantage of stimulating mucosal immune responses, due
to their oral route of immunization. Oral delivery pro-
vides RASVs with the opportunity to invade and
colonize the intestinal gut-associated lymphoid tissues
(GALT), where they actively interact with the host im-
mune system to stimulate robust humoral, mucosal and* Correspondence: kenneth.roland@asu.edu
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unless otherwise stated.cellular immune responses [2]. To allow the vaccine cells
to reach the intestinal tissues more rapidly, human sub-
jects are frequently required to fast prior to immunization
as a means to clear the gastrointestinal tract of food [3].
However, fasting also causes the gastric pH of humans to
fall below 2.0 [4,5]. This poses a non-trivial challenge to
the success of the immunization, as Salmonella species,
particularly S. Typhi [6], are not particularly resistant to
low pH (succumbing below pH 3.0), and the mutations
necessary for attenuation in RASVs often impose add-
itional sensitivity to acid [7-11]. Our lab has constructed
RASV strains exhibiting regulated-delayed attenuation
[12]. These S. Typhi-derived RASVs, χ9633(pYA4088),
χ9639(pYA4088) and χ9640(pYA4088), are susceptible to
a number of environmental stresses, including low pH
[13]. To administer an acid-sensitive vaccine strain via
the oral route, the vaccine must be given using a strat-
egy that not only actively protects the vaccine cellsntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cine viability or the development of an immune response
following vaccination.
Most researchers address the problem of low gastric
pH by administering an antacid such as sodium bicar-
bonate prior to the RASV [14-17]. The antacid rapidly
neutralizes the gastric acid, allowing the vaccine cells to
transit the gastric compartment under neutral or mildly
acidic conditions [18,19]. This combination of a liquid
RASV formulation with antacid is highly effective and
promotes the development of protective immune re-
sponses [20,21]. However, bicarbonate is not without
problems. In order to efficiently neutralize gastric acid, a
surprisingly large volume of bicarbonate must be given,
as gastric mixing is not efficient enough to thoroughly dis-
perse small volumes of bicarbonate completely through-
out the stomach [22,23]. In addition, bicarbonate has a
rather unpleasant taste to most palates and efforts to im-
prove this aspect will positively enhance the experience of
the volunteers in a clinical trial or vaccinees receiving li-
censed vaccines. Flavoring agents are sometimes added to
vaccine formulations for this reason [24].
In preparation for a clinical trial to assess the three
RASV strains listed above, we wanted to investigate the
administration of high concentrations of protein as an
alternative to bicarbonate. Protein is capable of buffering
gastric acid and raises the gastric pH within minutes of
ingestion [25,26]. As a food-borne pathogen, Salmonella
appears to take advantage of this gastric acid buffering
during infection scenarios. In the presence of protein-
rich food, the infectious dose of Salmonella is signifi-
cantly lower than in the absence of food [27]. Thus, we
hypothesized that the administration of protein, specific-
ally Ensure® Nutrition shakes, immediately prior to and
following immunization would provide the same protec-
tion from the low pH gastric environment as bicarbon-
ate. Using Ensure® also provides a carrier with a taste
likely to be more pleasant than bicarbonate for most
vaccinees. We examined the survival of S. Typhi wild
type and vaccine strains when suspended in Ensure® or a
bicarbonate solution and how these compounds, when
administered to mice with a low gastric pH, influenced
survival during gastric transit.
Results
Survival of recombinant attenuated Salmonella Typhi
vaccine strains in bicarbonate and Ensure®
To be an effective vaccine formulation, the carrier or co-
administered substance must not negatively affect the
viability of the vaccine cells. We monitored the effect of
bicarbonate and Ensure® (milk chocolate flavor) on the
viability of the three S. Typhi vaccine strains and model
S. Typhimurium strain for four hours (Figure 1). Most of
the S. Typhi strains, including χ9633, χ9639, ISP1820and Ty2, and both of the S. Typhimurium strains we
tested underwent a statistically significant increase in
numbers when incubated in Ensure®, indicating that
Ensure® could support the growth of these strains. Cell
numbers of strains suspended in bicarbonate tended to
decrease over time, but the decrease was statistically
significant only for strain Ty2 (T0 vs T4, p = 0.035)
(Figure 1B). Interestingly, there were no significant
changes in cell numbers for strains χ8438 and χ9640 in
either bicarbonate or Ensure® (Figure 1C). There were
statistical differences in the numbers of cells recovered
from Ensure compared to bicarbonate at the 2 and 4 h
time points for a number of strains (Figure 1A, B, D),
primarily due to the fact that Ensure® apparently sup-
ported the growth of these strains while bicarbonate did
not. We also examined survival in vanilla and strawberry
Ensure® and the flavor did not affect strain viability (data
not shown).Bicarbonate and Ensure® protect vaccine cells during low
pH gastric transit
Another characteristic of an effective RASV delivery for-
mulation is that it must protect cells from the low pH of
the gastric environment. To examine the ability of bicar-
bonate and Ensure® to combat gastric pH, these were
used to buffer the stomach pH of mice. Because the gas-
tric pH of a fasted mouse is about pH 4.0 and the gastric
pH of a fasted human is about pH 1-2 [4,5,28], gastric acid
secretion was induced in mice by subcutaneous histamine
injection (see Methods section) prior to immunization to
better mimic the situation in humans. Using this protocol,
the pH in the mouse stomach is reduced to around 1.5
[29]. Mice received either bicarbonate or Ensure® prior to
and immediately following immunization. Control mice
received no treatment. Vaccine viability was measured fol-
lowing gastric transit (Figure 2). Compared to the no
treatment group, administration of Ensure® significantly
increased the number of viable cells that reached the small
intestine for two of the S. Typhi strains and for the S.
Typhimurium strain (p = 0.0019 for χ9633(pYA4088), p =
0.0256 for χ9640(pY4088) and p = 0.0006 for χ9558
(pYA4088). This was a 599-, 75.0- and 647-fold increase,
respectively, in the geometric mean number of viable cells
to reach the ileum. Bicarbonate similarly improved the sur-
vival of χ9640(pYA4088) (p = 0.0190) and χ9558(pYA4088)
(p = 0.0379) during gastric transit, resulting in a 41.0- and
8.79-fold increase in the geometric mean number of cells
to reach the ileum, respectively. Administration of bicar-
bonate did not significantly impact the survival of χ9633
(pYA4088) or χ9639(pYA4088) (p = 0.2317 and 0.4945, re-
spectively) compared to the no treatment controls.
The Ensure treatment was better than bicarbonate at
increasing the gastric transit survival of strains χ9633
Figure 1 Survival of Salmonella vaccine and wild-type parent strains in Ensure and sodium bicarbonate. (A) S. Typhi strains χ9633 and
χ3744; (B) S. Typhi strains χ9639 and χ3769; (C) S. Typhi strains χ9640 and χ8438; (D) S. Typhimurium χ9558 and χ3761. Percent CFU/ml was calculated
as follows: (# CFU at tn/# CFU at t0) x 100 for each strain. Wild-type strains that exhibited a significant increase (p < 0.05) in the number of viable cells
in Ensure over viable cells in bicarbonate are marked with an asterisk (*). Vaccine strains exhibiting a significant increase in viable cells (p < 0.05)
between Bicarbonate and Ensure treatments are marked with a double asterisk (**). Data are the combined results of three independent experiments.
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Interestingly, the survival of strain χ9639(pYA4088) was
not impacted by either Ensure or bicarbonate treatments
(Figure 2B). Further, this strain survived gastric transit
in mice that did not receive bicarbonate or Ensure®
somewhat better than the other S. Typhi strains
(Figure 2A, B, C) although the difference was not statis-
tically significant (p = 0.06).
Discussion
The vast majority of clinical RASV trials have made use
of sodium bicarbonate as a means to protect vaccine
cells from low gastric pH. In fact, field trials with the li-
censed typhoid vaccine strain Ty21a demonstrated that
the administration of bicarbonate produced a superior
immune response as compared to other vaccine formu-
lation strategies [30,31]. Our results are consistent with
the idea that ingestion of a buffering substance prior to
oral immunization promotes the survival of vaccine
cells. The administration of bicarbonate prior to and im-
mediately following immunization significantly improvedthe survival of both S. Typhi χ9640(pYA4088) and S.
Typhimurium χ9558(pYA4088) during gastric transit.
Interestingly, strain χ9640(pYA4088) was the most im-
munogenic, among the three S. Typhi strains tested
here, in a recent clinical trial [32]. Sodium bicarbonate is
generally regarded as safe, and has been shown to have
no effect on the viability of wild-type Salmonella [33].
Our results demonstrated that high concentrations of
protein administered before and after immunization can
act as a substitute for bicarbonate. Ensure® provided a
greater degree of protection from the gastric environ-
ment than bicarbonate for S. Typhi strain χ9633
(pYA4088, pWSK129) (Figure 2A) and S. Typhimurium
strain χ9558(pYA4088, pWSK129) (Figure 2D), and pro-
vided protection equivalent to bicarbonate for S. Typhi
strain χ9640(pYA4088, pWSK129) (Figure 2C). No effect
of bicarbonate or Ensure® was observed for the rpoS Ty2
derivative, S. Typhi strain χ9639(pYA4088, pWSK129)
(Figure 2B).
Neither sodium bicarbonate nor Ensure® was able to
significantly increase the survival of χ9639(pYA4088)
Figure 2 Survival of RASV strains during low pH gastric transit. Histamine-treated mice were inoculated orally with 109 CFU of (A) χ9633
(pYA4088, pWSK129), (B) χ9639(pYA4088, pWSK129), (C) χ9640(pYA4088, pWSK129) or (D) χ9558(pYA4088, pWSK129). Mice received either 1.3%
sodium bicarbonate, chocolate Ensure® or no treatment prior to and immediately following immunization to neutralize gastric acid. The number
of viable vaccine cells in the small intestine was quantified one hour after immunization. Data are presented as the number of CFU/g intestine of
individual mice, with the geometric mean of the group displayed as a solid horizontal line. Groups that exhibited a significant increase (p < 0.05)
in the number of viable vaccine cells in the small intestine over the control group are marked with an asterisk (*). Groups exhibiting a significant
difference (p < 0.05) between Bicarbonate and Ensure treatments are marked with a double asterisk (**). Data are the combined results of two
independent experiments (8 mice total).
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four RASV strains tested in this study, χ9639 is the only
rpoS mutant, due to the fact that parent strain Ty2 car-
ries a mutation in rpoS [34]. Salmonella rpoS mutants
are significantly more sensitive to low pH than strains
with a functional RpoS because they are unable to sus-
tain an acid tolerance response (responsible for protect-
ing cells against low pH) for more than 20 minutes [7].
The problem may have been exacerbated by the presence
of the ΔPfur81::TT araC PBAD fur mutation in χ9639, as
Fur and RpoS jointly regulate induction of the acid toler-
ance response [7,35]. The amount of Fur present in a
ΔPfur81::TT araC PBAD fur S. Typhi mutant is substantially
lower than a wild-type strain, regardless of the arabinose
concentration during growth and, with regard to survival
at low pH, is indistinguishable from a fur deletion mutant
(29). Note that strain χ9640 is also a derivative of Ty2, but
in this strain, the rpoS gene has been replaced with a func-
tional gene from ISP1820 (parent of χ9633). The S. Typhi-
murium strain χ9558 has a functional rpoS gene, since its
parent is RpoS+. Thus, it is likely that a functional rpoS is
required in order to benefit from bicarbonate and Ensure
treatment, at least in this genetic background.Conclusions
The Ensure® nutrition shake was able to act as a substi-
tute for bicarbonate during oral inoculation to enhance
bacterial survival during passage through a low gastric
pH compartment. Ensure® provided protection better
than or equivalent to bicarbonate for all of the strains
tested. The failure of both Ensure® and bicarbonate to
protect an rpoS mutant during gastric transit suggests
that in future clinical trials, investigators should carefully
evaluate the degree of protection necessary for the spe-
cific RASV strain being evaluated and perform a careful
evaluation of the buffering agent used to neutralize gas-
tric pH.
Methods
Bacterial strains, plasmids and culture conditions
The bacterial strains and plasmids used in this study are
listed in Table 1. Strain χ9633 is derived from S. Typhi
ISP1820, an RpoS+ strain. Strains χ9639 and χ9640 are de-
rived from parent strain Ty2, which is RpoS−. Strain
χ9640 was rendered RpoS+ by transduction [13]. For rou-
tine use, strains were propagated in LB medium (which
contains 0.1% glucose) [36] supplemented with 0.05%
Table 1 Salmonella vaccine strains and plasmids used in this study
Strain Salmonella Serovar Genotype/Phenotypea Reference
χ9558 Typhimurium Δpmi-2426 Δ(gmd-fcl)-26 ΔPfur81::TT araC PBAD fur ΔPcrp527::TT araC PBAD crp ΔasdA27::TT araC PBAD c2
ΔaraE25 ΔaraBAD23 ΔrelA198::araC PBAD lacI TT ΔsopB1925 ΔagfBAC811, RpoS
+
[39]
χ9633 Typhi ISP1820 ΔPcrp527::TT araC PBAD crp ΔPfur81::TT araC PBAD fur Δpmi-2426 Δ(gmd-fcl)-26 ΔrelA198::araC PBAD lacI TT
ΔaraE25 ΔaraBAD23 ΔtviABCDE10 ΔagfBAC811 ΔsopB1925 ΔasdA33, RpoS+
[13]
χ9639 Typhi Ty2 ΔPcrp527::TT araC PBAD crp ΔPfur81::TT araC PBAD fur Δpmi-2426 Δ(gmd-fcl)-26 ΔrelA198::araC PBAD lacI TT
ΔaraE25 ΔtviABCDE10 ΔagfBAC811 ΔsopB1925 ΔasdA33, RpoS−
[13]
χ9640 Typhi Ty2 ΔPcrp527::TT araC PBAD crp ΔPfur81::TT araC PBAD fur Δpmi-2426 Δ(gmd-fcl)-26 ΔrelA198::araC PBAD lacI TT
ΔaraE25 ΔtviABCDE10 ΔagfBAC811 ΔsopB1925 ΔasdA33, RpoS+
[13]
χ3761 Typhimurium wild type [40]
χ3744 Typhi ISP1820 wild type [41]
χ3769 Typhi Ty2 rpoS [42]
χ8438 Typhi Ty2 RpoS+ [43]
Plasmid Descriptionb
pWSK129 pSC101 ori, Kanr [44]
pYA3493 pBR ori, Asd+ vector with bla SS-based periplasmic antigen secretion [45]
pYA4088 Encodes the α-helical region of PspA (aa 3-285) in pYA3493 [46]
aIn genotype descriptions, the subscripted number refers to a composite deletion and insertion of the indicated gene. P, promoter; TT, T4 ip III
transcription terminator.
bori, replication of origin; SS, secretion signal; Kanr, kanamycin resistance.
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included KT broth, which is a proprietary medium used
to support rapid, high-density bacterial growth, similar in
composition to terrific broth [13]. For antibiotic selection
of strains containing pWSK129, kanamycin was used at a
concentration of 30 μg/ml. All chemicals were purchased
from Sigma-Aldrich (St. Louis, MO, USA) or Thermo
Fisher Scientific (Pittsburgh, PA, USA) unless otherwise
indicated.
Formulation stability assays
Strains were grown in KT broth to an optical density at
600 nm of 2.0, then were pelleted and resuspended in
phosphate buffered saline (PBS) at 5 x 1010 CFU/ml.
Cells were diluted 1:15 into either a 1.3% sodium bicar-
bonate solution or Ensure® Nutrition shake (milk choc-
olate flavor) and incubated at 37°C for four hours.
Viability at each time point was assessed by serial dilu-
tion and plating onto LB agar containing 0.2% arabinose.
Gastric transit assays
This study was approved by the Arizona State University
Institutional Animal Care and Use Committee. Six week
old, female BALB/c mice (Charles River Laboratories,
Wilmington, MA, USA) were fasted without food or
water for 6 h prior to the start of the experiment. Mice
received the histamine H1-receptor antagonist chlor-
pheniramine (0.3 mg/kg) subcutaneously to prevent al-
lergy/anaphylaxis symptoms. Prior to inoculation, low
gastric pH was induced by subcutaneous injection of
histamine dihydrochloride (10 mg/kg) [37,38]. All bac-
terial strains used in the gastric transit assays containedthe low copy number plasmid pWSK129 (Kanr) to allow
for precise quantitation of strain numbers in the non-
sterile environment of the gastrointestinal tract. We did
not observe any Kanr organisms in the normal intestinal
flora of the mice. Strains were grown to late log phase
(optical density at 600 nm of 0.9), then pelleted and re-
suspended in PBS at a concentration of 5 x 1010 CFU/
ml. Groups of 5 mice were orally inoculated 50 min after
the administration of histamine [29]. For each inocula-
tion, the low gastric pH was treated with sodium bicar-
bonate, Ensure, or left untreated. Groups that were
treated with bicarbonate received 40 μl of a 1.3% sodium
bicarbonate solution orally 10 minutes prior to inocula-
tion and an additional 10 μl 10 minutes after [17].
Groups that were treated with Ensure received 20 μl of
Ensure® Nutrition shake (milk chocolate flavor) 10 mi-
nutes prior to inoculation and an additional 20 μl 10
minutes after [32]. Mice were euthanized 1 h after inocu-
lation and the entire small intestine was removed, homog-
enized and serially diluted. Samples were plated onto LB
agar containing 0.2% arabinose with kanamycin to deter-
mine the number of viable bacteria present following low
pH gastric transit.
Statistical analyses
All statistical analyses were performed using GraphPad
Prism version 6.00 for Windows (GraphPad Software, La
Jolla California USA). Statistical analyses of data from
the gastric transit assays were performed using the
Mann-Whitney test. Survival curves were analyzed using
Sidak’s multiple comparison test.
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